Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A, Heinemann V, Holch JW, von Einem JC, Westphalen CB, Heinrich K, Schlieker L, Jelas I, Alig AHS, Fischer LE, Weiss L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Kirchner T, Jung A, Stintzing S. Stahler A, et al. Among authors: heinrich k. Int J Cancer. 2021 Dec 1;149(11):1935-1943. doi: 10.1002/ijc.33747. Epub 2021 Jul 31. Int J Cancer. 2021. PMID: 34310714
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Modest DP, Heinemann V, Folprecht G, Denecke T, Pratschke J, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Held S, Stahler A, Heinrich K, von Einem JC, Stintzing S, Neumann UP, Ricard I. Modest DP, et al. Among authors: heinrich k. Ann Surg Oncol. 2020 Jul;27(7):2389-2401. doi: 10.1245/s10434-020-08219-w. Epub 2020 Mar 14. Ann Surg Oncol. 2020. PMID: 32172334 Free PMC article. Clinical Trial.
Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials.
Stahler A, Heinemann V, Ricard I, von Einem JC, Giessen-Jung C, Westphalen CB, Michl M, Heinrich K, Miller-Phillips L, Jelas I, Stintzing S, Modest DP. Stahler A, et al. Among authors: heinrich k. J Cancer Res Clin Oncol. 2020 Aug;146(8):2077-2087. doi: 10.1007/s00432-020-03290-y. Epub 2020 Jun 19. J Cancer Res Clin Oncol. 2020. PMID: 32561975 Free PMC article. Review.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Schulz C, Heinemann V, Heinrich K, Haas M, Holch JW, Fraccaroli A, Held S, von Einem JC, Modest DP, Fischer von Weikersthal L, Kullmann F, Moehler M, Scheithauer W, Jung A, Stintzing S. Schulz C, et al. Among authors: heinrich k. Anticancer Drugs. 2020 Sep;31(8):856-865. doi: 10.1097/CAD.0000000000000965. Anticancer Drugs. 2020. PMID: 32639280 Clinical Trial.
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
Kurreck A, Heinemann V, Fischer von Weikersthal L, Decker T, Kaiser F, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Graeven U, Schwaner I, Stahler A, Heinrich K, Jung A, Held S, von Einem JC, Stintzing S, Giessen-Jung C, Modest DP. Kurreck A, et al. Among authors: heinrich k. Eur J Cancer. 2020 Sep;137:81-92. doi: 10.1016/j.ejca.2020.06.010. Epub 2020 Aug 1. Eur J Cancer. 2020. PMID: 32750502 Clinical Trial.
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
Stahler A, Stintzing S, von Einem JC, Westphalen CB, Heinrich K, Krämer N, Michl M, Modest DP, von Weikersthal LF, Decker T, Kiani A, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Kaiser F, Kirchner T, Jung A, Heinemann V. Stahler A, et al. Among authors: heinrich k. Eur J Cancer. 2020 Sep;137:250-259. doi: 10.1016/j.ejca.2020.07.003. Epub 2020 Aug 15. Eur J Cancer. 2020. PMID: 32810748 Clinical Trial.
Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
Thurmaier J, Heinemann V, Engel J, Schubert-Fritschle G, Wiedemann M, Nüssler NC, Ruppert R, Kleeff J, Schepp W, Löhe F, Karthaus M, Neumann J, Kumbrink J, Taverna F, Stahler A, Heinrich K, Westphalen CB, Holch JW, Kirchner T, Michl M. Thurmaier J, et al. Among authors: heinrich k. Int J Cancer. 2021 Apr 15;148(8):1919-1927. doi: 10.1002/ijc.33364. Epub 2020 Dec 2. Int J Cancer. 2021. PMID: 33113215
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
Heinrich K, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Kaiser F, Graeven U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Giessen-Jung C, Stahler A, Michl M, Held S, Jung A, Kirchner T, Stintzing S, Heinemann V. Heinrich K, et al. Eur J Cancer. 2021 Apr;147:128-139. doi: 10.1016/j.ejca.2021.01.025. Epub 2021 Feb 27. Eur J Cancer. 2021. PMID: 33647548 Free article. Clinical Trial.
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A, Heinemann V, Schuster V, Heinrich K, Kurreck A, Gießen-Jung C, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Neumann J, Kirchner T, Jung A, Kumbrink J, Stintzing S, Modest DP. Stahler A, et al. Among authors: heinrich k. Eur J Cancer. 2021 Nov;157:71-80. doi: 10.1016/j.ejca.2021.08.017. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34507244 Clinical Trial.
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Alig AHS, Heinemann V, Geissler M, Fischer von Weikersthal L, Decker T, Heinrich K, Held S, Weiss L, Fischer LE, Moosmann N, Stahler A, Jelas I, Kurreck A, von Einem JC, Reinacher-Schick AC, Tannapfel A, Giessen-Jung C, Stintzing S, Modest DP. Alig AHS, et al. Among authors: heinrich k. Cancers (Basel). 2022 Jan 21;14(3):526. doi: 10.3390/cancers14030526. Cancers (Basel). 2022. PMID: 35158793 Free PMC article.
499 results